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hasing Troponin
ow Low Can You Go
f You Can See the Rise?*
llan S. Jaffe, MD, FACC
ochester, Minnesota
ecently, a visiting professor made a comment about not
hasing increased troponin values. He expressed the frus-
ration of clinicians who struggle with deciding how to
valuate patients with these increases and when to do it
cutely and when more chronically. Recent data have started
o put the pieces of this puzzle together in a way that many
f us suspected it would and in doing so suggest a new
aradigm that may help this difficult area.
See page 1755
One piece of the puzzle comes from the article published
n this issue of the Journal by Waxman et al. (1). Although
t lacks some covariates with which to evaluate their data, it
uggests that detectable levels of troponin, even ones below
he putative 99th percentile, are predictive of an increased
isk of death during hospital stay. The potency of the effect
a near doubling of the risk of death) in 2 different hospital
ohorts with values theoretically within the normal range
ut still detectable compared with those who had undetect-
ble values are impressive. This is not the first time an effect
f detectable but putatively normal troponin results has been
eported. Kontos et al. (2) reported similar results, but they
ere thought due to a less-sensitive, early generation assay.
or the report by Waxman et al. (1), a more sensitive
lthough probably not the most sensitive troponin assay was
sed. These data and others (see the following) suggest that
hat we call the 99th percentile is an admixture of subjects,
ith values below the level of detection and a modest
umber of additional subjects with detectable levels who are
ikely not really normal. In theory, one might expect that
ormal subjects should not have any circulating troponin.
ndeed, the issue of how to generate a true normal range has
ecently been evaluated by a study that is helpful for the
ynthesis that is developing. Zethelius et al. (3) found that
he upper limit of normal in older subjects seemed to be
igher with a highly sensitive troponin assay than in
ounger subjects. These investigators asked whether values
hat were between the limit of detection of the assay and the
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Mayo Clinic and Mayo Medical School, Rochester, Minnesota. Dr. Jaffe
s a consultant for and has received research support from Dade Behring, Beckmand
oulter, and Roche Diagnostics. He is or has been a consultant for most of the
iagnostic companies that make troponin assays.9th percentile of the younger and older subjects were
ndicative of a normal change associated with aging or
omorbidity with prognostic significance in the older group.
n a recent report, they demonstrated that those with such
esults suffered increased cardiovascular death and events.
he patients studied by Waxman et al. (1) likely had acute
isease that might have explained detectable levels of
roponin. However, the increases in the study by Zethelius
t al. (3) more likely reflect chronic structural heart disease
ather than acute disease. Thus, there now are 3 reports
1–3) that raise the question of whether patients with
etectable values for troponin, even below the 99th percen-
ile, are not really normal. These data are in accord with the
ata of Wu et al. (4) who, using a prototype assay with a
0-fold increase in sensitivity, found that “normals” had
alues that were roughly 10-fold less than the cutoff values
eing used today. Indeed, one could argue that even those
alues described in “normals” could be related to the lack of
recision of the assay at very low levels.
The idea that detectable levels of cardiac troponin,
hether above or below the 99th percentile, can be associ-
ted with chronic heart disease is not new; but this is area
here the idea that detectable values are not normal allows
ne to investigate this area with more credibility. This
uthor has advocated that the troponin increases that occur
n patients with renal failure can be due to chronic structural
eart disease with cardiac injury rather than acute processes
nd that those patients should be treated as such, unless
alues are increasing (5). That does not mitigate their
rognostic importance but suggests a more chronic thera-
eutic approach. Recent data support the concept that
tructural heart disease can be responsible for detectable
alues both below and above the putative 99th percentile.
chultz et al. (6), in an angiographic study, found that 69%
f patients with structural heart disease (either coronary
isease or an elevated left ventricular end-diastolic pressure)
ad detectable levels of troponin, albeit below the 99th
ercentile, whereas 74% of those with normal hemodynamic
tatus and without coronary artery disease had undetectable
alues. The implications of those data are clear; structural
eart disease can cause detectable troponin values. These
ata have been further elaborated in the recent Dallas heart
tudy (7) in which a large cohort was studied. This was not
normal cohort but simply a representative population. In
hat study, 0.7% had troponin values above the 99th
ercentile. The 99th percentile is the lower limit of detection
or the assay used in that study; therefore one could not probe
etween those values. Although 0.7% is small for the popu-
ation at large, it might be substantially enriched in the
ospital setting. In the group with increases, which were
inor to modest, almost all of the subjects had some
ardiovascular disease, either heart failure, renal failure, an
levated left ventricular mass, or diabetes. Thus the in-
reases were not in “normals” but in patients with heart
isease. It is likely that these subjects are at increased risk.
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Editorial Comment November 7, 2006:1763–4hese data suggest that cardiac troponin, in addition to
elping to diagnose acute cardiovascular disease, might also
e a more chronic risk marker. This would fit nicely with
he data fromWaxman et al (1) in patients who are critically
ll, the data from Zethelius et al. (3), and those with renal
ailure. The mechanisms for this are likely many and beyond
he scope of this editorial.
If this is the correct formation, how does it help us in
hasing cardiac troponin? It suggests 2 strategies. First, it is
ery likely from a large body of data that the way to make
he distinction between those with acute heart disease and
his modest number of patients with structural heart disease
ho have increases is by looking for rising values. Renal
atients with acute coronary syndromes raise their troponin
alues (8), as do patients who present with acute infarction
nd/or recurrent infarction (9). This is something that was
ssential with creatine kinase-myocardial band because of its
elative insensitivity and lack of specificity; so it should be a
amiliar concept, but such a strategy with troponin might be
qually efficacious.
There will, of course, be doubters. Sometimes the timing
ill not allow this analysis to be done, and when using
ardiac troponin T, there are occasional patients with
T-segment elevation myocardial infarction who have a
ouble peaked curve; and there will be occasional exceptions
o any rule, but this group will be modest. In some patients,
ooking for rising values will cause delay. However, this
trategy would only need to be implemented in those who
ave minor increases in troponin of questionable signifi-
ance. The increases that are structural are modest, so
atients who have substantial increases in troponin (decided
n an assay-by-assay basis) will not need to be evaluated by
ssessing change over time, and those at high risk will be
dmitted regardless of changes. In addition, recent data
uggest that if one uses the sensitive cutoff values advocated,
he diagnosis of acute myocardial infraction can be made in
ver 80% of patients within 2 to 3 h with rising values (10).
perationally, for now, this strategy will be complex.
ecause numerous assays are imprecise at low troponin
evels, the lower the value, the larger the change will need to
e. The traditional way to look at this from the point of view
f values that have poor imprecision around them is to use
SDs of the variation. These calculations can easily be done
or each assay to guide clinicians, but there will be unhap-
iness in having to learn still more numbers. However, this
ill only be a short-term paradigm until more sensitive
ssays are developed.
More sensitive assays are a must. Manufacturers know
ow to do this. Many choose not to because they worry that
he increased sensitivity will cause complaints from clini-
ians who are frustrated by their inability to find an etiologyor an increased troponin value and blame the assays. But
here are multiple advantages to more sensitive assays. The
rst is that there likely would be very significant negative
redictive value for a truly normal troponin. In addition,
uch assays would provide earlier diagnosis, because the
alues that are in the zone between the limit of detection
nd the 99th percentile would now be in the middle of the
iagnostic range and it would be easy to observe a rising
attern. Because these assays might only be needed in the
ubset of individuals for whom change is important, they
nitially might only be needed in the small subset of subjects
ho have a diagnostic uncertainty and low initial values.
To move in this direction, clinicians must educate them-
elves about the cardiac troponin assays they use locally and
ecome comfortable about how to interpret and act on the
alues. Patients who have acute increases with rises will
equire hospital care, but those with more chronic increases
ill not. These patients will require a new paradigm of
utpatient evaluation and follow-up to evaluate their under-
ying cardiovascular comorbidities. Sensitivity is the key.
e can go very low as long as we are sensitive to the rise.
eprint requests and correspondence: Dr. Allan S. Jaffe, Mayo
linic and Mayo Medical School, Rochester, Minnesota 55902.
-mail: Jaffe.Allan@Mayo.edu.
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